Previous Article | Next Article ![]()
Infection and Immunity, November 1999, p. 5664-5675, Vol. 67, No. 11
Children's Hospital Oakland Research
Institute, Oakland, California 94609
Received 7 June 1999/Returned for modification 13 July
1999/Accepted 6 August 1999
NspA is a highly conserved membrane protein that is reported to
elicit protective antibody responses against Neisseria
meningitidis serogroups A, B and C in mice (D. Martin, N. Cadieux, J. Hanel, and B. R. Brodeur, J. Exp. Med. 185:1173-1183,
1997). To investigate the vaccine potential of NspA, we produced mouse
anti-recombinant NspA (rNspA) antisera, which were used to evaluate the
accessibility of NspA epitopes on the surface of different serogroup B
strains by an immunofluorescence flow cytometric assay and by
susceptibility to antibody-dependent, complement-mediated
bacteriolysis. Among 17 genetically diverse strains tested, 11 (65%)
were positive for NspA cell surface epitopes and 6 (35%) were
negative. All six negative strains also were resistant to bactericidal
activity induced by the anti-rNspA antiserum. In contrast, of the 11 NspA surface-positive strains, 8 (73%; P < 0.05)
were killed by the antiserum and complement. In infant rats challenged
with one of these eight strains, the anti-rNspA antiserum conferred
protection against bacteremia, whereas the antiserum failed to protect
rats challenged by one of the six NspA cell surface-negative strains. Neither NspA expression nor protein sequence accounted for differences in NspA surface accessibility, since all six negative strains expressed
NspA in outer membrane preparations and since their predicted NspA
amino acid sequences were 99 to 100% identical to those of three
representative positive strains. However, the six NspA cell
surface-negative strains produced, on average, larger amounts of group
B polysaccharide than did the 11 positive strains (reciprocal geometric
mean titers, 676 and 224, respectively; P < 0.05),
which suggests that the capsule may limit the accessibility of NspA
surface epitopes. Given these strain differences in NspA surface
accessibility, an rNspA-based meningococcal B vaccine may have to be
supplemented by additional antigens.
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Differences in Surface Expression of NspA among
Neisseria meningitidis Group B Strains
*
Corresponding author. Mailing address: Children's
Hospital Oakland Research Institute, 747 Fifty Second St., Oakland, CA
94609. Phone: (510) 450-7640. Fax: (510) 450-7910. E-mail:
dgranoff{at}chori.org.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|